Analgesic effects of ketamine infusion therapy in korean patients with neuropathic pain: A 2-week, open-label, uncontrolled study  by Kang, Jin Gu et al.
Current Therapeutic Research
Volume 71, Number 2, April 2010
 93
Presented in part in poster form at the 28th Annual European Society of Regional Anaesthesia and Pain Therapy Congress, 
September 9, 2009, Salzburg, Austria.
Accepted for publication March 22, 2010. doi:10.1016/j.curtheres.2010.04.01
© 2010 Excerpta Medica Inc. All rights reserved. 0011-393X/$ - see front matter
Analgesic Effects of Ketamine Infusion Therapy in  
Korean Patients With Neuropathic Pain: A 2-Week, 
Open-Label, Uncontrolled Study
Jin Gu Kang, MD1; Chul Joong Lee, MD, PhD1; Tae Hyeong Kim, MD1;  
Woo Seok Sim, MD, PhD1; Byung Seop Shin, MD1; Sang Hyun Lee, MD1;  
Francis Sahngun Nahm, MD2; Pyung Bok Lee, MD2; Yong Chul Kim, MD, PhD3; 
and Sang Chul Lee, MD, PhD3
1Department of Anesthesiology and Pain Medicine, Samsung Seoul Hospital, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2Department 
of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, 
Republic of Korea; and 3Department of Anesthesiology and Pain Medicine, Seoul National 
University College of Medicine, Seoul, Republic of Korea
Abstract
Background: The overexcitation of the N-methyl-d-aspartate receptor complex 
appears to play a critical role in the development of neuropathic pain, and ketamine 
acts as an antagonist to that receptor. Some publications have reported on the promi-
nent relief of neuropathic pain with intravenous or subcutaneous ketamine infusions 
or a single-dose intravenous ketamine injection despite adverse effects.
Objectives: The primary objective of this study was to determine the analgesic 
effect of intravenous ketamine infusion therapy for neuropathic pain refractory to con-
ventional treatments. Secondary objectives included identifying the variables related to 
the analgesic effect and the pain descriptors susceptible to ketamine infusion.
Methods: This 2-week, open-label, uncontrolled study was conducted in Korean 
patients with neuropathic pain recruited from the Samsung Seoul Hospital (Seoul, 
Republic of Korea) outpatient pain management unit. Patients were required to have 
a pain severity score >5 (visual analog scale [VAS], where 0 = no pain and 10 = worst 
pain imaginable) over a period of ≥1 month while on standard treatment. The patients 
were required to have shown no benefit from standard treatment and no pain relief 
lasting over 1 month. The ketamine infusion therapy was composed of 3 sessions 
performed consecutively every other day. Midazolam was administered concomitantly 
to reduce the occurrence of central nervous system–related adverse events (AEs) sec-
ondary to ketamine. Each session was as follows: ketamine 0.2 mg/kg and midazolam 
0.1 mg/kg were administered intravenously for 5 minutes as a loading dose, followed 
by a continuous infusion of ketamine 0.5 mg/kg/h and midazolam 0.025 mg/kg/h 
for 2 hours. AEs were assessed in the following ways: close monitoring of ECG, blood 
pressure, oxygen saturation, and evaluating the need for treatment of AEs during infu-
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sion and until discharge by an attending anesthesiologist; an open question about 
discomfort at the end of each session; spontaneous reports about AEs during each ses-
sion; and the patients’ and caregivers’ checklist of AEs occurring at home for 2 weeks 
after discharge. All the descriptors of pain expressed by the patients in Korean were 
recorded and translated into appropriate English terminology on the basis of the lit-
erature on Korean verbal descriptors of pain. Each of the translated pain descriptors 
was then classified into 1 of 18 sensory items. 
Results: The overall VAS score for pain decreased from a baseline mean (SD) 
of 7.20 (1.77) to 5.46 (2.29) (P < 0.001) 2 weeks after treatment in 103 patients 
(53 males and 50 females; mean age, 52.56 [17.33] years) who completed the study. 
Variables such as age, sex, and the duration and diagnosis of pain were not found to 
be associated with analgesic effect. Seven of the 18 pain descriptors were found to have 
a significant response to ketamine infusion treatment between baseline and 2 weeks 
follow-up: burning pain (P = 0.008); dull, aching pain (P < 0.001); overly sensitive 
to touch (P = 0.002); stabbing pain (P = 0.008); electric pain (P = 0.031); tingl- 
ing pain (P < 0.001); and squeezing pain (P < 0.001). A total of 52 patients reported 
AEs: 33 during infusion and 44 during recovery and up to 2 weeks follow up. The 
most commonly reported AEs were snoring (15 [15%]) during infusion and dizziness 
(43 [42%]) during recovery.
Conclusions: Ketamine infusion therapy was associated with reduced sever-
ity of neuropathic pain and generally well tolerated for up to 2 weeks in these patients 
with neuropathic pain refractory to standard treatment. Variables such as sex, age, 
and the diagnosis and duration of pain had no association with the analgesic effect of 
this treatment. Randomized controlled trials are needed to evaluate the efficacy and 
tolerability of treatment with ketamine infusion. (Curr Ther Res Clin Exp. 2010;71: 
93–104) © 2010 Excerpta Medica Inc.
Key words: ketamine, infusion therapy, neuropathic pain, pain descriptor.
InTROduCTIOn
Because neuropathic pain is often resistant to NSAIDs and opioids,1–3 other medication 
classes, such as antidepressants, anticonvulsants, and local anesthetics, are used.2,4,5 
Central sensitization may mediate chronic neuropathic pain, even when ongoing 
peripheral sensory input is absent.6 A wind-up phenomenon leading to central sensi-
tization is postulated to be the cause of allodynia and hyperalgesia.6–8 Because over-
excitation of the N-methyl-d-aspartate (NMDA) receptor complex appears to play a 
critical role in the development of these phenomena, much research has been con-
ducted on the potential analgesic effects of NMDA-receptor antagonists on neuro-
pathic pain.9–11
Ketamine, a dissociative anesthetic, acts as a noncompetitive antagonist to the 
phencyclidine site of the NMDA receptor for the excitatory neurotransmitter gluta-
mate.12 Despite the reported adverse effects such as drowsiness, disorientation, dizzi-
ness, and hallucinations, some publications have been released on the prominent relief 
of neuropathic pain with intravenous13,14 or subcutaneous ketamine infusions,15 or a 
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single-dose intravenous ketamine injection.10,16 In a case report and a retrospective 
study by Correll et al,17,18 a complete remission of complex regional pain syndrome 
(CRPS) occurred in some patients who had failed to achieve pain relief from conven-
tional treatments. In a retrospective chart review, Webster and Walker19 reported that 
low-dose intravenous or subcutaneous ketamine infusions were well tolerated and 
effective for nonresponsive neuropathic pain in ambulatory outpatients. 
Based on these reports, we developed a protocol of ketamine infusion therapy (KIT) 
used in this study. Our objectives were to determine the analgesic effect of this KIT 
to be used as a treatment option in refractory neuropathic pain and evaluate the vari-
ables influencing its effect. The theoretical concept of a mechanism-based analysis of 
neuropathic pain presumes that a specific symptom predicts a specific underlying 
mechanism.20 Taking this concept into account, we also assessed which descriptions 
of pain were more responsive to KIT.
PATIenTs And MeThOds
Consecutive patients (aged 20–85 years) with neuropathic pain were recruited from 
the outpatient pain management unit at Samsung Seoul Hospital (Seoul, Republic of 
Korea) from October 2006 to September 2008. The institutional review board of 
Samsung Seoul Hospital approved the study, and written informed consent was ob-
tained from each patient prior to study participation.
To be included in the study, the patient’s mean daily pain intensity had to be >5 
on an 11-point visual analog scale (VAS) (where 0 = no pain and 10 = worst pain 
imaginable) over a period of ≥1 month while on standard treatments. In addition, the 
patients had to have not benefited from standard treatments and had no pain relief 
lasting over 1 month. Standard conventional treatments included: nonmedical (eg, 
physical therapy); pharmacologic monotherapy, or concomitant therapy with NSAIDs, 
antidepressants, benzodiazepines, anticonvulsants, low- or high-potency opioids, lido-
caine patch, or capsaicin cream; or interventional procedures (eg, selective nerve 
blocks, epidural analgesia, peripheral nerve blocks, sympathetic ganglion blocks, spi-
nal cord stimulation).
Exclusion criteria were severe psychiatric disease, a history of apoplexy, previous cardiac 
arrhythmia, abnormal ECG, angina pectoris, insufficient respiratory function, insufficient 
kidney function, pregnancy, present or past drug or alcohol abuse, and an inability to 
give informed consent. The patients continued their previously prescribed medications 
including NSAIDs, opioids, antidepressants, and anticonvulsants if the prescription 
dosage had been unchanged for >1 week before and during the entire study period.
The inclusion criteria were evaluated by 3 attending physicians (C.J.L., T.H.K., 
and W.S.S.) who also ascertained that subjects did not have any other medical condi-
tion that would affect their ability to safely take part in the study. It was clearly ad-
dressed that the patient’s participation was completely voluntary and could be termi-
nated at any time of request. Patients who did not consent to undergo KIT were 
continued on their previously prescribed medication.
Our KIT protocol consisted of 3 sessions of ketamine infusion, and each session was 
performed consecutively every other day. Patients were fasted for ≥9 hours prior to 
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each session of KIT and each patient received KIT at approximately the same hour of 
the day for each session. On the study day, patients were placed in a quiet room and 
monitored with a 3-lead ECG, a peripheral pulse oximeter, and an automated blood 
pressure (BP) device. An intravenous route was accessed in the nondominant or non-
symptomatic arm for intravenous fluid and drug administration, and oxygen (6 L/min) 
was given via a facial mask. Benzodiazepines have been demonstrated to attenuate the 
potential central nervous system (CNS) adverse events (AEs) associated with ketamine.21 
In the present study, midazolam was administered concomitantly with ketamine. In the 
presence of an anesthesiologist, IV ketamine* 0.2 mg/kg and IV midazolam 0.1 mg/kg 
(Bukwang Pharmaceutical Co., Seoul, Republic of Korea) were administered for 5 min- 
utes as a loading dose, followed by a continuous infusion of ketamine (0.5 mg/kg/h) 
and midazolam (0.025 mg/kg/h) for 2 hours using a programmable pump. Patients 
were determined to have recovered completely from KIT if they were no longer sleepy, 
attained full orientation to time, place, and person, and were not in need of treatment 
for AEs. On complete recovery, the patients were discharged from the outpatient 
recovery unit ≥1 hour after the end of each session of KIT and not without an accom-
panying reliable guardian or caretaker. AEs were assessed in the following ways: close 
monitoring of ECG, BP, oxygen saturation, and evaluating the need for treatment of 
AEs during infusion and until discharge by an attending anesthesiologist (J.G.K., 
B.S.S., and S.H.L.); an open question about discomfort at the end of each session; spon-
taneous reports about AEs during each session; and the patients’ and caregivers’ check-
list of AEs occurring at home after discharge. AEs were recorded based on whether 
they occurred during or after infusion, regardless of session. Multiple AEs were pos-
sible in a single patient but repeated AEs were only recorded once.
All patients were required to complete the VAS for pain assessment just before the 
initiation of the first, second, and third sessions of ketamine infusion (VAS1, VAS2, 
VAS3, respectively), and at 2 weeks after the third ketamine infusion (VASF). In ad-
dition to the patients’ characteristics, the following variables were recorded for analy-
sis: primary diagnosis, duration of pain, descriptors of pain before and 2 weeks after 
KIT, patient satisfaction, and AEs. Patient satisfaction was recorded at the 2-week 
follow-up as “Yes” or “No.”
All the descriptors of pain expressed by the patients in Korean were recorded 
and translated into appropriate English terminology on the basis of the literature on 
Korean verbal descriptors of pain (multiple descriptors per patient were possible).22 
Each of the translated pain descriptors was then classified into 1 of 18 sensory items 
according to the preliminary item set for a neuropathic pain assessment instrument 
by Krause and Backonja.23
Statistical analyses were carried out using SPSS version 12.0 (SPSS Inc., Chicago, 
Illinois). Data were presented as mean (SD) or number (%) of patients. The changes 
in the VAS score during the study period were analyzed using a repeated-measures 
ANOVA with post hoc analysis and a pairwise multiple comparison with Bonferroni 
*Trademark: Ketomin® (Daehan Pharmaceutical Company, Seoul, Republic of Korea).
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adjustment. To determine the variables that were related to the change in the VAS 
score, a binary logistic regression analysis was performed using age, sex, and the diag-
nosis and duration of pain before KIT. The susceptibility of the descriptor was ana-
lyzed using a McNemar test. P < 0.05 was considered statistically significant.
ResulTs
One hundred twenty-three Korean patients with neuropathic pain met the inclusion 
criteria but 15 patients refused to participate; therefore, 108 patients were enrolled in 
this study. A total of 5 study participants were excluded from the analysis: 2 partici-
pants took herbal medications after the first session of ketamine infusion; 1 partici-
pant did not take previously prescribed medication after the first session; 1 participant 
slipped on the way to the hospital for the second session and had an emergency opera-
tion; and 1 participant was lost to follow-up without reason after the first session. Ac-
cordingly, 103 patients (53 males and 50 females, aged 22–83 years) completed the 
study. The patients’ characteristics and diagnoses are summarized in Table I.
The baseline VAS score (VAS1, mean [SD]) was 7.20 (1.77). The VAS2 and VAS3 
scores decreased significantly to 6.28 (2.12) (P < 0.001) and 5.85 (2.36) (P < 0.001), 
respectively, compared with baseline (Table II). The VASF (5.46 [2.29]) was signifi-
cantly lower than the VAS1 (P < 0.001) and VAS2 (P = 0.003). Forty-eight patients 
(47%) had a decrease in the VAS score of >33% at 2 weeks after KIT compared with 
that of baseline and 19 patients (18%) had a decrease of >50%. The variables, includ-
ing age, sex, and the diagnosis and duration of pain before KIT, were not found to be 
associated with the changes in VAS score.
Table III shows the pain descriptors and their response to KIT. The descriptors 
retrieved from the patients reporting “Yes” for satisfaction at 2-week follow-up were 
defined as improved. The significantly improved descriptors were as follows: burning 
pain (38%, P = 0.008); dull, aching pain (44%, P < 0.001); overly sensitive to touch 
(37%, P = 0.002); stabbing pain (47%, P = 0.008); electric pain (36%, P = 0.031); 
tingling pain (36%, P < 0.001); and squeezing pain (50%, P < 0.001).
Fifty-two patients (50%) overall experienced AEs. Thirty-three patients (32%) 
experienced AEs during the infusion of ketamine. Snoring (n = 15 [15%]) was the 
most common AE. Other frequent AEs included the following: involuntary move-
ment (7 [7%]); decreased heart rate (>20% decrease in heart rate from preinfusion 
baseline) (7 [7%]); decreased BP (>10% decrease in mean arterial BP [MABP] from 
preinfusion baseline) (5 [5%]); and increased BP (>10% increase in MABP from pre-
infusion baseline) (2 [2%]). These patients presenting AEs were closely monitored, 
but did not require intervention or treatment because the AEs were considered toler-
able and mild. Forty-four patients (43%) reported AEs during recovery after ketamine 
infusion and at home. The most commonly expressed AEs were dizziness (43 [42%]), 
nausea (7 [7%]), dry mouth (2 [2%]), and decreased BP (2 [2%]). Among them only 
3 patients required intravenous antiemetics for nausea; the other patients did not 
require treatment for the AEs and recovered spontaneously. Complications related to 
KIT were not found after 2 weeks, and 56 patients (54%) reported that they were 
satisfied with KIT at the 2-week follow-up.
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dIsCussIOn
This study found that KIT had an analgesic effect for the treatment of neuropathic 
pain without serious AEs for up to 2 weeks. There are insufficient data to support the 
long-term use of ketamine for chronic pain24; however, a recent review by Visser and 
Schug25 listed articles that reported the analgesic efficacy of ketamine for various 
types of neuropathic pain such as postherpetic neuralgia, CRPS, spinal cord injury, 
trigeminal neuralgia, and stump and phantom limb pain. In the present study, the 
effect of KIT was observed for 2 weeks, which may be inadequate to support its long-
term effect. 
Table I.  Demographic and clinical characteristics of Korean patients with neuropathic 
pain (N = 103).
Variable Value
Age, y
  Mean (SD) 52.56 (17.33)
  Range 22–83
Sex, no. (%)
  Male 53 (51)
  Female 50 (49)
Duration of pain, mo
  Mean (SD) 25.65 (30.12)
  Range 1–144
Diagnosis of pain, no. (%)*
  Postherpetic neuralgia 44 (43)
  Complex regional pain syndrome type 1/2 36 (35)/3 (3)
  Postthoracotomy pain syndrome 5 (5)
  Failed back surgery syndrome 5 (5)
  Spinal cord injury 3 (3)
  Plexopathy 3 (3)
  Trigeminal neuralgia 2 (2)
  Diabetic polyneuropathy 2 (2)
Current medication, no. (%)*
  Anticonvulsants 71 (69)
  Antidepressants 49 (48)
  Tramadol/tramadol + acetaminophen 43 (42)/13 (13)
  Benzodiazepines 29 (28)
  Opioids/NSAIDs 18 (17)/10 (10)
  Capsaicin cream/lidocaine patch/other 2 (2)/3 (3)/4 (4)
  No medication 15 (15)
Patients under physical therapy, no. (%) 15 (15)
*Totals may not equal 100% due to rounding.
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In the present study, 47 patients (46%) reported that they were not satisfied with 
KIT. Possible explanations might be that they had pain mechanisms other than 
NMDA-dependent pathway or our protocol of KIT did not achieve a therapeutic 
blood level of ketamine in those patients. There are several subunits of the NMDA 
receptor, and the NMDA receptors containing a specific subunit appear particularly 
important for nociception.26 A low blood level of ketamine may block a different 
subunit from a higher blood level showing analgesic effect.27 Unfortunately, we did 
not measure the plasma concentration of ketamine in the present study. On the other 
hand, Webster and Walker19 proposed that pain reduction is most likely a product of 
time and dose and also suggested that the duration of infusion might be more impor-
tant than the blood level. In randomized clinical trials assessing efficacious medica-
tions (eg, antidepressants, gabapentin, and pregabalin) for neuropathic pain, typically 
<50% of patients experience satisfactory pain relief.28 It has been suggested that 10% to 
15% of patients with neuropathic pain are truly refractory to all forms of pharma- 
cotherapy.27,29 Considering the inclusion criteria of our study, the satisfaction rate of 
54% might be meaningful.
The responder rate in this study was analyzed by definition of a 50% reduction in 
VAS score compared with baseline30 or a 33% reduction.31,32 However, we did not 
define a “treatment responder” when planning this study because we thought that any 
reduction of pain compared with baseline might be meaningful to the participants 
who had been unresponsive to multiple conventional treatments. As a result, 47% of 
participants had a reduction of >33% of the VAS score, which was similar to that of 
satisfaction (54%). In addition, because the patients recruited in this study had neu-
ropathic pain resistant to other treatment and a relatively high mean baseline VAS 
score (7.20), the results might have been different if we had treated the patients with 
KIT on admission to the pain management unit.33
This KIT protocol was designed for outpatients with consideration for tolerability, 
monitoring and analgesic effects. Webster and Walker19 reported the tolerability of 
Table II.  The visual analog scale (VAS) scores for pain assessment just 
before the initiation of the first, second, and third sessions of 
ketamine infusion (VAS1, VAS2, VAS3, respectively) and at 
2 weeks after the third ketamine infusion (VASF) in Korean 
patients with neuropathic pain (N = 103).
 VAS Score,  
Time mean (SD) P
VAS1 7.20 (1.77) –
VAS2 6.28 (2.12) <0.001*
VAS3 5.85 (2.36) <0.001*
VASF 5.46 (2.29) <0.001*; 0.003†
*Compared with VAS1.
†  Compared with VAS2.
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a prolonged (≤8 weeks) continuous intravenous administration of ketamine in their study, 
where mean duration of ketamine infusion (range) was 16.4 (5–55) days in 13 outpatients. 
However, a continuous infusion of ketamine outside the hospital is not practical.
Previously, there has been no consensus on a single, uniform ketamine protocol or 
dose. The ketamine infusion regimen in this study used the upper marginal doses of 
ketamine from ranges mentioned in other studies.24,31,34 A search of MEDLINE in 
English (inception–2009) using terms such as ketamine, NMDA antagonist, pain, and 
Table III.  Response to pain descriptors in patients who received ketamine infusion thera- 
py. Data are number (%) of patients (N = 103).
Descriptor*
Frequency 
at Baseline†
Unimproved 
at 2 Weeks‡ P§
Tingling pain 39 (38) 25 (24) <0.001
Dull, aching pain 27 (26) 15 (15) <0.001
Overly sensitive to touch 27 (26) 17 (17) 0.002
Squeezing pain 24 (23) 12 (12) <0.001
Burning pain 21 (20) 13 (13) 0.008
Stabbing pain 17 (17) 9 (9) 0.008
Electric pain 16 (16) 10 (10) 0.031
Sharp pain 12 (12) 9 (9) 0.25
Shooting pain 9 (9) 5 (5) 0.125
Numbness 8 (8) 6 (6) 0.5
Tearing pain 7 (7) 4 (4) 0.25
Freezing pain 7 (7) 3 (3) 0.125
Itching pain 3 (3) 1 (1) 0.5
Grinding pain 2 (2) 1 (1) 1.0
Throbbing pain 1 (1) 0 NA
Cramping pain 1 (1) 1 (1) NA
Pinching pain 1 (1) 1 (1) NA
Soreness 0 – NA
NA = not applicable.
* Eighteen sensory items according to the preliminary item set for a neuropathic pain assessment 
instrument by Krause and Backonja.23
† Multiple pain descriptors were possible in a patient, so counts total >103.
‡  We defined the descriptor as improved if a patient reporting “Yes” for satisfaction reported the im- 
proved status for that descriptor at the 2-week follow-up. The rest of the descriptors were considered 
as unimproved.
§  The susceptibility of the descriptor to the ketamine infusion therapy at 2-week follow-up compared with 
before therapy using a McNemar test.
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neuropathic pain, found few studies regarding the effect of the diagnosis of pain, age, 
sex, and duration of pain on the effect of KIT. The duration of pain did not influence 
the outcome of the present study. 
In a previous report, the analgesic benefit appeared to be more pronounced in 
younger patients with a shorter history of pain (<5 years).35 In this open-label, uncon-
trolled study only 7 women (aged 47–79 years) with chronic orofacial pain were en-
rolled. The 3 youngest patients (aged 43–53 years) in this study with pain <3 years 
showed prolonged pain relief, while 3 of the 4 oldest patients (aged 57–79 years) with 
pain >5 years did not, with response to one or several injections lasting only 3 days. 
To the best of our knowledge, the present study is the first to report on the relation-
ship between the analgesic effect of KIT and the relation to pain, age, and sex. And, 
although the total number of patients was not large, those variables appeared to have 
no influence on the outcome.
Ketamine is known to act as an antihyperalgesic and antiallodynic compound in 
pain management.25 Based on the concept of mechanism-based analysis20,36 we ana-
lyzed the change of pain descriptors to find out the mechanisms or the descriptors that 
were influenced by ketamine. In this study, 7 descriptors were determined to be sig-
nificantly more susceptible to KIT. Among them, “overly sensitive to touch” has been 
associated with mechanical dynamic allodynia or mechanical punctuate hyperalgesia.36 
“Burning pain” has been associated with spontaneous pain.20 Both pain descriptors are 
thought to be involved with NMDA receptors36 and had a significant response to KIT 
in this study. The mechanism of “electric pain” is thought to be peripheral nociceptor 
hyperexcitability through sodium channels,20,36 and this descriptor also had a signif-
icant response to KIT. This finding is in accordance with a previous report that sug-
gests that ketamine acts as a pain modulator, targeting sodium channels as well as 
NMDA receptors.37 On the other hand, these results might indicate that NMDA 
receptors have a partial role in evoking “electric pain.” The mechanisms of other sus-
ceptible pain descriptors have not been uncovered, but our findings suggest that 
NMDA receptors or sodium channels are involved in evoking those descriptors. KIT 
may be considered as a treatment option for neuropathic pain with susceptible pain 
descriptors that affect NMDA receptors.
One risk of using ketamine for neuropathic pain is the occurrence of CNS AEs such as 
dizziness, dysphoria, and hallucinations.12 Benzodiazepines have been demonstrated to 
attenuate CNS AEs associated with ketamine.21 In the present study, midazolam was 
administered in a bolus dose followed by a continuous infusion until the end of the keta-
mine infusion to help with these AEs. This might explain why none of the patients in 
the present study complained of unacceptable AEs such as hallucinations or dysphoria. 
On the other hand, midazolam might have caused other AEs during administration.38
limitations
There was no placebo or control group and, therefore, the changes in VAS and pain 
descriptors might have been due to other factors not related to KIT. Subjects were 
recruited at a single university hospital, which poses problems in terms of the gener-
alizability of our findings. Patients were followed up for only 2 weeks. Only the VAS 
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and a yes-or-no question of satisfaction were used to evaluate the effect. These measure-
ments are not sufficient to evaluate the treatment effectiveness objectively. The existing 
medications for neuropathic pain that patients had before and during the study may 
have affected the results; however, the medication was unchanged for 1 week before in-
clusion and during the entire study period. Finally, there might have been a change of 
language nuance in translating Korean pain descriptors into English terminologies. Ran-
domized, controlled studies are needed to evaluate the efficacy and safety profile of KIT 
and to explore the role of KIT in a mechanism-based analysis of neuropathic pain.
COnClusIOns
Ketamine infusion therapy was associated with reduced severity of neuropathic pain 
and generally well tolerated for up to 2 weeks in these patients with neuropathic pain 
refractory to standard treatment. Variables such as sex, age, and the diagnosis and 
duration of pain had no association with the analgesic effect of this treatment.
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